Time to Pull the Plug on Unaccountable PBM Middlemen

Morning Consult
Draining the “Washington Swamp” is a staple of today’s political and campaign discourse. But there also exists a health policy “swamp” brought to light at the recent Health, Education, Labor and Pensions Committee hearing regarding the prescription drug distribution chain…Read More.


Berkley Research Group
Within the U.S. healthcare system, the flow of dollars in the pharmaceutical marketplace is a complex process involving a variety of stakeholders and myriad rebates, discounts, and fees…View the Report.

PBMI Report Shows Changes in Pharmacy Benefit Design to Meet Cost Challenges

Although employers continue to cite managing drug cost trend as the number one goal, they are addressing this challenge head on by implementing significant changes in drug benefit design…View the Report.


USC Schaeffer
US spending on prescription drugs has been growing rapidly, prompting calls for government intervention to slow the upward trend…View the Report.

Senate takes aim at pharmacy benefit managers’ role in rising drug costs

Modern Medicine
Amid concerns about the escalating cost of prescription drugs, the Senate’s Health, Education, Labor, and Pensions (HELP) Committee held hearings this summer to frame the Senate’s efforts moving forward…Read More.

Perverse Market Incentives Encourage High Prescription Drug Prices

Perverse Market
Pharmacy benefit managers (PBMs) are the under-discussed market participants who manage prescription drug insurance for the vast majority of Americans…Read More.

Flurry Of Federal And State Probes Target Insulin Drugmakers And Pharma Middlemen

Kaiser Health News
Five states and a federal prosecutor are demanding information from insulin manufacturers and the pharmaceutical industry’s financial middlemen, seeking answers about their business relationships and the soaring price of diabetes drugs…Read More.

FTC, FDA To Probe Generic Competition, PBMs, Purchaser Consolidation

Inside Health Policy
An upcoming public workshop spearheaded by the Federal Trade Commission and FDA will delve into possible incentives for generic market entry, what can be done to address tactics used to stall generic competition, the role intermediaries play in drug pricing and how FTC can address these issues….Read More.

63% of employers say PBMs not transparent about how they make money

Becker’s Hospital Review
Only 30 percent of respondents said they understand the details of their PBM contracts, and 40 percent said they understand their PBM’s performance guarantees…Read More.

Cummings Investigates Reports That Plans, PBMs Favor Addictive Opioids Over Expensive, Less-Addictive Drugs

Inside Health Policy
Health plans and pharmacy benefit managers make it difficult for people to get less-addictive pain killers while making it easier for them to get cheaper, highly-addictive drugs….Read More.

Twitter   LinkedIn